Generic drug maker Par Pharmaceutical announced that it will restate financial results for 2004 and 2005 and the first quarter of 2006 which will reduce earnings for that period by $55 million. The adjustment is the result of an understatement of accounts receivable reserves. Par now faces class-action suits for violating sections of the Securities Exchange Act of 1934. Report